Yourgene Health PLC Capital Markets Day
November 06 2019 - 7:52AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
06 November 2019
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Capital Markets Day
Manchester, UK 6 November 2019: Yourgene (AIM: YGEN), a leading
international molecular diagnostics group, announces that it held a
Capital Markets Day for analysts and institutional investors in
London yesterday afternoon.
The Capital Markets Day provided an overview of Company strategy
and featured presentations from the senior management team
alongside a presentation from a Key Opinion Leader:
Presenters on the day included:
- Lyn Rees, Chief Executive Officer
- Hayden Jeffreys, Chief Operating Officer
- Barry Hextall, Chief Financial Officer
- Dr. Stephen Little, Founder and Vice Chair
- Dr. Matthew C. Forman, Head of Bioinformatics & Software
- Professor Basky Thilaganathan, Director, Fetal Medicine Unit
and Clinical Lead, The SAFE test laboratory
The presentation made at the Capital Markets Day is available on
the Company's website to download and a video of the presentation
will be made available in due course here:
https://www.yourgene-health.com/investors/company-information/investor-presentations
No new material information was disclosed.
Yourgene Health plc Tel: +44 (0)161 667 1053
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Stifel Nicolaus Europe Limited (Sole Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations) Mob: 07980 541 893 Mob: 07584 391 303
Paul McManus / Lianne Cawthorne
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate
molecular diagnostic solutions, primarily for reproductive health.
The Group's products include non-invasive prenatal tests (NIPT) for
Down's Syndrome and other genetic disorders, Cystic Fibrosis
screening tests, invasive rapid aneuploidy tests, male infertility
tests and genetic disease tests. Yourgene's commercial footprint is
already established in the UK, Europe, the Middle East, Africa and
Asia.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions. Through our technical
expertise and partnerships, Yourgene Health is also extending its
genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore, and is listed on the London Stock
Exchange's AIM market under the ticker "YGEN". For more
information, visit www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUGGBCGUPBGWQ
(END) Dow Jones Newswires
November 06, 2019 08:52 ET (13:52 GMT)
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Premaitha (LSE:NIPT)
Historical Stock Chart
From Jul 2023 to Jul 2024